thehansindia.com
Researchers find mechanisms that may lead to IBD
The findings point to an immune-cell change that may happen before Crohn’s symptoms appear, which could help predict relapse or guide future therapies. That could eventually affect monitoring or new treatment strategies for people with IBD.
Researchers studying IBD immune mechanisms, clinicians interested in biomarkers and disease prediction, and patients following IBD research and future treatment developments.
What To Know
Researchers at Mount Sinai report that gamma delta intraepithelial lymphocytes (gamma delta IELs) in the gut are reduced before clinical signs of Crohn’s-like ileitis in a mouse model and that loss of these cells may shift the balance toward pro-inflammatory responses.
The team suggests gamma delta IEL loss might serve as a predictive biomarker for relapse and that boosting these cells’ function could be explored as a therapeutic strategy.
This article summarizes a Science Immunology paper and highlights the potential role of gamma delta T cells in maintaining intestinal immune balance and preventing progression to chronic inflammation. It does not provide clinical recommendations or human trial results.
If you want the original study, look for the March 2025 Science Immunology article by the Mount Sinai group for full methods and data.
This report summarizes preclinical (mouse-model) research described in a scientific journal. Mouse findings don’t directly translate into new treatments or diagnostic tests for people yet. The news piece is a secondary summary; review the original Science Immunology paper for study design, limitations, and direct evidence supporting the claims.
